GlobalData on MSN6d
AstraZeneca gains NICE nod for lung cancer drugs Tagrisso and ImfinziTagrisso and Imfinzi are projected to generate global sales of $8bn and $7bn, respectively, by 2030, according to GlobalData.
AstraZeneca has received two positive recommendations from the National Institute for Health and Care Excellence (NICE) for ...
Even before the FDA's recent approval of Dato-DXd in breast cancer, analysts predicted sales of the antibody-drug conjugate ...
AstraZeneca (AZ) has received two separate recommendations from the National Institute for Health and Care Excellence (NICE) ...
Enhertu’s label expansion comes on the heels of the FDA’s approval of the partners' Datroway for a related type of breast ...
UK pharma major AstraZeneca today revealed that, this week, it has received two positive recommendations from the National ...
Zacks.com on MSN7h
FDA Expands Label of AZN's Enhertu for New Breast Cancer IndicationAstraZeneca AZN and partner Daiichi Sankyo announced that the FDA has approved the supplemental biologics license application ...
Osimertinib, also known as Tagrisso and made by AstraZeneca, can help stop cancer from returning after surgery ...
AstraZeneca announced that this week it has received two positive recommendations from the National Institute for Health and Care Excellence (NICE) for the treatment of lung cancer patients across ...
The approval is based on findings from a phase 3 study which demonstrated the drug’s superiority over chemotherapy.
News Medical on MSN3d
AstraZeneca receives positive NICE recommendations for lung cancer treatmentAstraZeneca announced that this week it has received two positive recommendations from the National Institute for Health and Care Excellence (NICE) for the treatment of lung cancer patients across ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback